Document is current
Any future updates will be listed below
-
Authors
Roberts, Jason A. https://orcid.org/0000-0001-6218-435X
Sime, Fekade B. https://orcid.org/0000-0003-4061-2063
Lipman, Jeffrey https://orcid.org/0000-0002-5965-9876
Hernández-Mitre, María Patricia https://orcid.org/0000-0003-3565-0292
Baptista, João Pedro https://orcid.org/0000-0002-6790-806X
Brüggemann, Roger J. https://orcid.org/0000-0002-7618-725X
Darvall, Jai https://orcid.org/0000-0003-0579-8931
De Waele, Jan J. https://orcid.org/0000-0003-1017-9748
Dimopoulos, George https://orcid.org/0000-0002-3784-3103
Lefrant, Jean-Yves https://orcid.org/0000-0002-7774-2497
Mat Nor, Mohd Basri
Rello, Jordi https://orcid.org/0000-0003-0676-6210
Seoane, Leonardo https://orcid.org/0000-0001-9262-6673
Slavin, Monica A. https://orcid.org/0000-0002-8443-314X
Valkonen, Miia
Venditti, Mario https://orcid.org/0000-0003-2639-0281
Ceccarelli, Giancarlo https://orcid.org/0000-0001-5921-3180
Wong, Wai Tat
Zeitlinger, Markus https://orcid.org/0000-0002-1873-3953
Roger, Claire https://orcid.org/0000-0002-6055-0034
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03136926 at ClinicalTrials.govDocuments that mention this clinical trial
Are contemporary antifungal doses sufficient for critically ill patients? Outcomes from an international, multicenter pharmacokinetics study for Screening Antifungal Exposure in Intensive Care Units—the SAFE-ICU study
https://doi.org/10.1007/s00134-025-07793-5
-
Funding
Funding for this research was provided by:
Royal Brisbane and Women's Hospital Foundation
European Society of Clinical Microbiology and Infectious Diseases
ESCMID PK/PD of Anti-Infectives Study Group
International Society of Antimicrobial Chemotherapy (ISAC) Infections in the ICU and Sepsis Working Group
Gilead Australia Fellowship (14500)
The University of Queensland
- License Information
-
More Information
Article History
Received: 15 October 2024
Accepted: 8 January 2025
First Online: 3 February 2025
Declarations
:
: JA Roberts has consulted or provided lectures for Qpex, Gilead, Advanz Pharma, Sandoz, Pfizer, MSD, Gilead and Cipla. JJ De Waele has consulted for Biomerieux, Menarini, Monlycke, MSD, Pfizer, Roche Diagnostics, ThermoFisher and Viatris (fees and honoraria paid to institution).
